• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Proton pump inhibitors and colorectal cancer: A systematic review

    2021-12-06 08:54:42AgastyaPatelPiotrSpychalskiMagdalenaAntoszewskaJaroslawRegulaJarekKobiela
    World Journal of Gastroenterology 2021年44期

    Agastya Patel, Piotr Spychalski, Magdalena Antoszewska, Jaroslaw Regula, Jarek Kobiela

    Abstract

    Key Words: Colorectal cancer; Proton pump inhibitor; Carcinogenesis; Cancer epidemiology; Capecitabine; Translational medicine

    INTRODUCTION

    Proton pump inhibitors (PPI) are among the most widely prescribed medications globally[1 ,2 ]. Since their development in the 1980 s, these drugs have been used for conditions such as peptic ulcer disease, gastroesophageal reflux disease, stress gastritis, and gastrinomas[3 ]. PPI are available by prescription, but are also sold overthe-counter resulting in frequent use without appropriate indication[4 ,5 ]. The mechanism of action of PPI involves irreversible, long-lasting binding to and inhibition of the hydrogen-potassium adenosine triphosphatase (ATPase) enzyme system on gastric parietal cells[6 ]. These ATPase pumps are responsible for secreting H+ions into the gastric lumen, resulting in the production of gastric acid. Suppression of gastric acid production by PPI lowers the acidity of gastric contents while causing feedback hypergastrinemia.

    Gastrin, in turn, is a potent growth factor involved in several physiological and pathological processes, including neoplastic transformation[7 ]. One hypothesis suggests that gastrin may have pro-inflammatory properties and can stimulate the tumor microenvironmentviamacrophage activation and chemotaxis. It is therefore possible that PPI and the resultant hypergastrinemia have a cancer-promoting effect[8 ].

    Some studies, however, suggest that PPI may also exert anti-tumor properties.These drugs might paradoxically inhibit the proliferative effects of hypergastrinemia while demonstrating anti-oxidant, anti-inflammatory, and pro-apoptotic activity[9 ].PPI could also have a potential chemotherapeutic role by reducing tumor resistance to chemotherapeutics. De Militoet al[10 ] reported that manipulating cancer pH may sensitize them to certain chemotherapeutics. In contrast, the TRIO-013 /LOGiC trial demonstrated that PPI may negatively affect the efficacy of some cytotoxic drugs,possibly due to alkalinization of the gastric environment[11 ].

    Overall, concerns are increasing regarding the safety of PPI use because of induced hypergastrinemia and a possible association with gastrointestinal (GI) cancer risk,including colorectal cancer (CRC). Many current patients with CRC may have a history of PPI use, but precise epidemiological data are not available. Ahnet al[12 ] and Maet al[13 ] have summarized observational studies assessing the association of PPI use with the risk of developing CRC. Ahnet al[12 ] found no significant effect of PPI on CRC risk, whereas Maet al[13 ] found a weak association between long-term PPI use (>5 years) and increased CRC risk. However, there are no systematic reviews summarizing the evidence from basic research studies exploring mechanisms by which PPIs may affect CRC and from human epidemiological and clinical studies examining PPI use in the context of CRC survival and treatment. As a systematic review might identify important epidemiological and clinical findings, our aim was to provide a comprehensive report on the association of PPI use and CRC based on recent basic research and human studies.

    MATERIALS AND METHODS

    Literature search

    This systematic review was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement using PICO(patients, interventions, comparisons, outcomes)-based questions. Following a predefined search strategy, we searched the MEDLINE, EMBASE, Web of Science, and Scopus online databases to identify suitable articles. No filters were applied during the search, and we also performed backward citation chaining of eligible full-text studies.

    Evidence acquisition

    On May 17 , 2021 , two independent researchers (AP, PS) performed a search of the target online databases for eligible studies. The search string was (“proton pump inhibitors”or “proton pump inhibitor”or “ppis”or“ppi”or “omeprazole”or “pantoprazole”or “esomeprazole”) and (“CRC”or “colorectal cancer”or “colon cancer”or “rectal cancer”).The preliminary search returned 2591 articles, which two independent researchers(AP, PS) screened. The entire protocol is presented in a PRISMA flowchart(Supplementary Figure 1 ).

    Inclusion and exclusion criteria

    We used PICO framework-based research questions for this review (Supplementary Table 1 ). If articles met predefined criteria, they were included and categorized as basic research (animal and cell studies), epidemiological (incidence and mortality studies), and treatment studies. Articles were excluded if the full text was not available or was not in English, were not original articles, or did not conform with PICO.

    Evidence synthesis and Quality Assessment:

    Two independent researchers (Patel A and Spychalski P) retrieved and summarized information from the eligible studies in tables. The authors (Patel A, Spychalski P,Antoszewska M and Kobiela J) discussed conflicts regarding inclusion of studies and resolved them by consensus. Two independent researchers (Patel A and Antoszewska M) assessed the quality of included case-control and cohort studies using the Newcastle-Ottawa scale (NOS)[14 ]. This scale awards a maximum of nine points for each of the following items: Selection (four stars), comparability (two stars) and outcomes (three stars). Studies were considered of high quality if they scored seven or more stars on NOS assessment. Additionally, the Cochrane Risk of Bias 2 .0 tool was used to assess bias in randomized controlled studies included in the retrospective post-hoc analysis reports[15 ]. The results of quality assessment are described in Supplementary Material along with Supplementary Table 2 .

    RESULTS

    A total of 28 studies were included in the review: Basic research studies (n = 12 )[animal models (n= 5 ), CRC cell lines (n = 1 ), or both (n = 6 )]; epidemiological studies (n= 11 ) [analyzing CRC risk (n = 9 ) and survival (n = 2 ) associated with PPI use]; and treatment studies (n= 5 ), examining the effects of PPI on CRC chemotherapy regimens.

    Basic studies

    The included basic studies examined two primary themes: (1 ) Trophic effects of PPIinduced hypergastrinemia; and (2 ) Potential chemotherapeutic role of PPI as cytostatic drugs, chemosensitizing drugs, or T lymphokine-activated killer cell-originated protein kinase (TOPK) inhibitors. The information from the basic studies is summarized in Tables 1 (animal models) and 2 (CRC cell lines).

    Trophic studies:The trophic effects of PPI-induced hypergastrinemia were investigated in six studies[16 -21 ]. Four animal studies demonstrated that PPI-induced hypergastrinemia did not influence growth and invasiveness of CRC[16 -19 ]. These studies showed that omeprazole treatment resulted in significantly higher serum or plasma gastrin levels (4 - to 20 -fold across studies) in comparison to control groups.However, the treated and control groups were similar in terms of tumor burden and/or invasiveness of CRC. Graffneret al[16 ] found omeprazole-treated and control mice to be similar in terms of tumor size, survival and distant metastasis rate. Pinsonet al[17 ] compared low-dose and high-dose omeprazole, ranitidine (histamine-2 receptor antagonist), and control exposure in rats. They found that overall tumor burden and survival were similar among these groups but documented significantly lower mean tumor number, volume, and total mass in the ranitidine group (multiple comparisons,allP< 0 .05 ). Hurwitz et al[18 ] reported concordant findings in their study, additionally noting no significant differences in DNA, RNA or protein concentration in tumor-free colonic tissues of treatedversuscontrol rats. Chenet al[19 ] performed sham operation,colostomy and/or fundectomy, omeprazole treatment, or fasting with refeeding to assess the short-term and long-term effects of hypergastrinemia. None of the groups demonstrated growth of CRC tumors, but the fundectomy group showed suppressed tumor growth.

    Two studies indicated that PPI treatment resulted in suppression of CRC growth[20 ,21 ]. Penman et al[20 ] found a significantly lower incidence of CRC tumors in omeprazole-treated rats than controls (63 % vs 95 %, P < 0 .02 ). They hypothesized that omeprazole possibly influenced metabolism of the carcinogen (azoxymethane) by affecting either intestinal microflora or P450 isoenzymes, therefore resulting in lower CRC growth. Working with the NCI-H719 human colon cancer cell line, Tobi et al[21 ]demonstrated a dose-dependent decrease in proliferation (cytostatic effect) with omeprazole, but noted no such effect in two other cell lines (DLD-1 and LCC-18 ).These researchers found that the cytostatic effect of omeprazole persisted even when omeprazole was combined with gastrin, suggesting a potential paradoxical inhibition of gastrin’s trophic influence on CRC.

    Chemotherapeutic studies:Six studies addressed the potential chemotherapeutic role of PPI in CRC[22 -27 ]. Three studies assessed the cytotoxic effects – anti-proliferative,pro-apoptotic, and anti-inflammatory properties – of PPI on CRC and found that PPI(omeprazole, pantoprazole) dose-dependently inhibited proliferation and induced apoptosis in CRC models[22 -24 ]. Patlolla et al[22 ] reported that omeprazole resulted in upregulation of p21 waf1 /cip1 and downregulation of cyclin A, Bcl-2 , Bcl Xl, and survivin expression, leading to induction of cell apoptosis. Kimet al[23 ] reported on the anti-inflammatory activities of PPI, describing reduced tumor necrosis factor-alpha(TNF-α), nitric oxide (NO), colon thiobarbituric acid-reactive substance (TBA-RS), and expression of cyclooxygenase-2 (COX-2 ) and NO synthetase. These authors also suggested a potential anti-proteolytic and anti-mutagenic action of PPI, reporting decreased levels of matrix metalloproteinase (MMP)-9 , MMP-11 , and MT1 -MMP and decreased beta-catenin accumulation in omeprazole-treated mice as compared to controls.

    Hanet al[24 ] reported similar findings on the pro-apoptotic, anti-inflammatory, and anti-proliferative properties of PPI, along with a potential anti-angiogenic effect. They found that PPI treatment reduced expression of angiogenic factors such as interleukin(IL)-8 , platelet-derived growth factor, vascular endothelial growth factor, and hypoxiainducible factor 1 -alpha. Moreover, Kim et al[23 ] and Han et al[24 ] demonstrated that PPI may paradoxically inhibit the trophic effect of gastrin on CRC cells. Kimet al[23 ]found cell proliferation to be significantly (P< 0 .05 ) reduced in cells treated with both omeprazole and gastrin compared to with gastrin only. Hanet al[24 ] reported similar findings and found that PPI antagonized gastrin’s binding to cholecystokinin B receptor (CCKBR), both alone and in combination with gastrin.

    Table 1 Summary of basic research studies (animal models)

    AOM: Azoxymethane; CRC: Colorectal cancer; COX-2 : Cyclooxygenase-2 ; F: Female; 5 -FU: 5 -Fluorouracil; ILA: Ilaprazole; IMHC: Immunohistochemistry; IP: Intraperitoneal; M: Male; MAPK: Mitogen-activated protein kinase; MMP:Matrix metalloproteinase; NO: Nitric oxide; NE: No effect; NR: Not reported; OME: Omeprazole; PAN: Pantoprazole; PO: Per os; PPI: Proton pump inhibitors; PE: Protective effect; SC: Subcutaneous; TOPK: T lymphokine-activated killer cell-originated protein kinase; TNF-α: Tumor necrosis factor-alpha; TBA-RS: Thiobarbituric acid-reactive substance.

    Wanget al[25 ] found that PPI increased the chemosensitivity of human colon cancer cells (HT29 and RKO lines) as PPI combined with 5 -fluorouracil (5 -FU) resulted in significantly higher cell inhibition rates than 5 -FU alone (in vitro experiment: P = 0 .04 ;in vivoexperiment:P= 0 .03 ).

    Table 2 Summary of basic research studies (colorectal cancer cell lines)

    Zenget al[26 ] and Zheng et al[27 ] investigated pantoprazole and ilaprazole,respectively, as potential TOPK inhibitors. Both groups found that PPI inhibited CRC cell growthviaTOPK inhibitionin vitroandin vivo. Among the PPI, ilaprazole and pantoprazole showed the strongest affinity for TOPK. Zenget al[26 ] examining three colon cancer cell lines with different TOPK expression levels reported that pantoprazole had a growth-inhibiting effect through interaction with TOPK. Zhenget al[27 ] described similar results for ilaprazole, with PPI treatment resulting in decreased phosphorylation of histone, a TOPK-mediated process, suggesting that TOPK may be a direct target for these drugs. Furthermore, the authors found ilaprazole to be an inducer of apoptosisviaactivation of caspases and cleavage of poly-(ADP-ribose) polymerase.

    Epidemiological studies

    Six case-control studies[28 -33 ], two prospective studies[34 ,35 ], and one retrospective study[36 ] addressed the incidence of CRC in PPI-usersversusnon-users. Two retrospective cohort studies assessed the survival of CRC patients in relation to PPI use.

    Incidence studies:The information from the six included case-control incidence studies is abstracted in Table 3 [28 -33 ]. The time definition of PPI use varied across studies. The included studies analyzed information from healthcare databases or registries of different regions – Denmark, the Netherlands, United Kingdom, San Francisco (United States), and Washington (United States). A total of 31829 CRC patients matched with 276647 controls were included in this review. After adjustment for confounders, none of the studies revealed an increased risk of CRC in current or ever PPI-users in comparison to non-users. Furthermore, most (5 /6 ) of the studies found that the duration of PPI use or average daily dose of PPI did not influence CRC risk[28 -30 ,32 ,33 ]. However, Lee et al[31 ] reported that the risk of CRC increased significantly with ≥ 10 years of PPI use compared to no use [odds ratio (OR) = 1 .28 ,95 % confidence interval (CI): 1 .15 -1 .44 ]. Robertson et al[28 ], Yang et al[30 ] and Kuiperet al[33 ] did not find any significant increase in risk in recent or former PPI-users.However, Kuiperet al[33 ] found that current PPI-users were at an increased risk of developing CRC (OR = 1 .30 , 95 %CI: 1 .16 -1 .47 ), especially with concomitant nonsteroidal anti-inflammatory drugs use (OR=1 .57 , 95 %CI: 1 .27 -1 .93 ).

    Three cohort studies assessed the hazard of developing CRC in PPI-users and nonusers[34 -36 ] (Table 4 ). The review included a total of 108107 PPI-users and 609800 nonusers identified through healthcare databases in Korea, United States, and Taiwan.Hwanget al[34 ] and Babic et al[35 ] found no significant association between PPI exposure and CRC development, but Leiet al[36 ] reported a significantly increased risk of CRC among PPI-users [hazard ratio (HR) = 2 .03 , 95 %CI: 1 .56 -2 .63 , P < 0 .05 ].Hwanget al[34 ] reported that PPI use was associated with increased CRC risk in individuals at low risk for CRC (non-obese, non-diabetics, female, aged < 50 years, no history of alcoholism, receiving ≥ 180 daily defined dose of PPI) (HR = 12 .30 , 95 %CI:1 .71 -88 .23 , P < 0 .01 ). Babic et al[35 ] found that the period of PPI use had no effect on CRC risk but that current PPI use was associated with a decreased risk (HR = 0 .82 ,95 %CI: 0 .68 -0 .98 ). In contrast, Lei et al[36 ] reported a time-dependent and dosedependent relationship between PPI use and CRC development, with patients at higher risk if they were using PPI for ≥ 1 year and increasing doses of PPI. On further analysis, Leiet al[36 ] found that the risk of CRC was increased with esomeprazole,lansoprazole, and omeprazole, but no such association was seen with pantoprazole and rabeprazole.

    Survival studies:Survival of CRC patients was assessed in two retrospective studies.Grahamet al[37 ] included 1304 CRC (117 PPI-users at diagnosis) patients with similar baseline characteristics, but greater cardiac comorbidities in PPI-users (P< 0 .05 ). The authors found similar overall survival (OS) rates at 1 -, 2 - and 5 -years between PPIusers and non-users, but the cumulative survival of PPI-users was significantly shorter than non-users (1775 vs 2279 d, P = 0 .048 ). Furthermore, after controlling for known risk factors, the risk of mortality was significantly higher in CRC patients using PPI(HR = 1 .34 , 95 %CI: 1 .01 -1 .78 , P = 0 .04 ). Tvingsholm et al[38 ] analyzed cancer-specific mortality for nine cancers in a cohort of 347919 patients, including 47188 CRC patients.They found that the risk of mortality in CRC patients was approximately 12 times higher in PPI-users as compared to non-users (HR = 11 .8 , 95 %CI: 11 .3 -12 .4 ).

    Treatment studies

    The effects of PPI use concurrently with chemotherapeutic treatment of CRC wasassessed in three retrospective studies, two post-hoc analyses of randomized controlled trials (RCTs)[39 -43 ]. These studies cumulatively examined 7065 patients and are summarized in Table 5 .

    Table 3 Summary of epidemiological studies assessing the exposure of proton pump inhibitors in colorectal cancer patients

    Zhanget al[39 ] examined 125 patients with stage II-III rectal cancer dichotomizing them as eligible omeprazole users (EOU, 20 mg per os at least once/day for 6 d and/or 40 mg IV infusion daily during adjuvant chemotherapy) or non-EOU, and an effective omeprazole group (EOG, OME ≥ 200 mg total during the study period), or a non-EOG.The authors found that 5 -year disease-free survival (DFS) was significantly decreased in the EOGvsnon-EOG group (P= 0 .032 ), but OS was similar among the groups (P=0 .092 ). Additionally, the recurrence of rectal cancer was more common in the non-EOG group than in the EOG group (31 .3 % vs 10 .3 %, P = 0 .025 ). A comparison of EOU and non-EOU patients revealed similar DFS and OS at 3 and 5 years.

    In a cohort of 298 patients with stage I-III CRC, Sun et al[40 ] identified 77 patients who used PPIs concurrently during adjuvant capecitabine therapy. PPI-users were found to have significantly lower 5 -year recurrence-free survival (RFS) (74 % vs 83 %,P= 0 .03 ), but similar OS (81 % vs 78 %, P = 0 .7 ) compared to non-users. Multivariate analysis revealed similar RFS between the groups (HR = 1 .65 , 95 %CI: 0 .93 -2 .94 ,P=0 .09 ).

    Table 4 Summary of epidemiological studies assessing the effect of proton pump inhibitors exposure on the risk of developing colorectal cancer

    Wonget al[41 ] studied PPI use with adjuvant CapeOx (capecitabine, intravenous oxaliplatin), or adjuvant FOLFOX (intravenous 5 -FU, leucovorin, oxaliplatin) therapy.Of 389 patients with stage II-III CRC, 214 underwent CapeOx therapy and 175 had FOLFOX therapy. The proportions of patients taking PPI in both groups were similar(23 .4 % CapeOx vs 28 % FOLFOX, P = 0 .3 ). Comparing PPI-users and non-users, the authors found 3 -year RFS to be significantly lower in CapeOx-treated PPI-users (P=0 .029 ) but similar between the two groups in FOLFOX-treated patients (P = 0 .66 ).Multivariate analysis showed that PPI use was associated with increased risk of CRC recurrence in the CapeOx-treated group (HR = 2 .20 , 95 %CI: 1 .14 -4 .25 , P = 0 .018 ). The use of PPI in combination with either adjuvant treatment regimen did not affect 3 -year OS in this study (CapeOx,P= 0 .35 ; FOLFOX, P = 0 .929 ).

    Kichenadasseet al[42 ] analyzing data from six RCTs including metastatic CRC patients reported that PPI-users had significantly poorer OS (HR = 1 .20 , 95 %CI: 1 .03 -1 .40 , P = 0 .02 ) and PFS (HR = 1 .20 , 95 %CI: 1 .05 -1 .37 , P = 0 .009 ). The subgroup analysis revealed that chemotherapy type, use of capecitabine or 5 -FU, line of therapy and VEGF inhibitor use, across studies, did not influence oncological outcomes between users and non-users. Kimet al[43 ] described post-hoc analysis of data relating to PPI use from the AXEPT trial. The authors reported that PPI users in the FOLFIRI(fluorouracil, leucovorin, irinotecan) arm had significantly better OS (HR = 0 .5 , 95 %CI:0 .30 -0 .85 ; P = 0 .011 ) and PFS (HR = 0 .55 , 95 %CI: 0 .33 -0 .91 , P = 0 .02 ) compared to nonusers, while there were no differences noted in the mXELIRI (capecitabine, irinotecan)arm.

    DISCUSSION

    This systematic review of 26 articles is the first in the literature to summarize the evidence on the association between PPI and CRC from basic research, epidemiological, and clinical treatment studies. Previously published meta-analyses by Ahnetal[12 ] and Ma et al[13 ] primarily focused on the epidemiological aspect, assessing the risk of CRC with PPI exposure. In this systematic review, we describe evidence from basic research studies on the potential pro-tumor (proliferative) and anti-tumor(therapeutic) effects of PPI, assess if these findings are translatable into human studies,and discuss future clinical and research aspects related to the use of PPI in patients with CRC.

    Table 5 Summary of treatment studies

    Although primarily responsible for gastric acid secretion, gastrin and its precursors are also potent growth factors for normal and malignant GI tissues[44 ]. Gastrin exerts its trophic effect through interaction with CCKBR, resulting in activation of growthpromoting downstream pathways[24 ,44 ]. As noted, long-term PPI use causes hypergastrinemia, raising concerns regarding the effects of PPI-induced hypergastrinemia on GI cancers. Recent reviews on the association of PPI use and various GI cancers such as pancreatic, hepatocellular, esophageal, and gastric cancer have yielded conflicting evidence[45 -47 ]. Previous reviews addressing PPI and CRC suggested that there may not be any causative association between them[12 -13 ]. However, Maet al[13 ] suggested that long-term PPI use (> 5 years) may increase CRC risk.

    Of the six basic research studies on PPI-induced hypergastrinemia, four demonstrated that PPI did not influence CRC growth and progression, whereas two suggested that PPI may even have a protective effect against CRC[16 ,17 ,19 -21 ]. The two publications reporting a suggested protective effect, by Penmanet aland Tobiet al[21 ], demonstrated a lower CRC tumor burden in PPI-treated animal models and a dose-dependent decrease in CRC cell line (NCL-H716 ) proliferation, respectively.These findings may be suggestive of an anti-tumor effect of this drug class or may be explained by a possible interaction with the carcinogen (azoxymethane) used for tumor induction (as Penmanet al[20 ] hypothesized).

    The included human epidemiological studies do not present compelling evidence of a causative relationship between PPI use and CRC. Seven of nine studies demonstrated no significant risk of CRC development in patients previously or currently using PPI[28 -35 ]. However, of these, Lee et al[31 ] reported an increased incidence with long-term use (≥ 10 years), whereas Hwang et al[34 ] found increased cases in a specific cohort of patients using PPI and at low risk of developing CRC. Of the remaining two studies, Lei and colleagues[36 ], found that the risk of CRC was significantly increased in PPI users while Kuiperet al[33 ] found significantly increased risk only in current PPI users, especially those using NSAIDs concomitantly. These results from human studies may be corroborative of the basic research findings that PPI do not have a growth-promoting effect on CRC. However, two included retrospective analyses examining survival among CRC patients, found that mortality risk was significantly higher in those using PPI compared to non-users[37 ,38 ]. In their cohort, Grahamet al[37 ] found any comorbidities, advanced tumor stage, and poor tumor differentiation to be significant predictors of mortality. Such data may depict a potential pro-tumor influence of PPI on the CRC microenvironment, in contrast to findings from basic research mentioned above. Another explanation for poorer survival seen in PPI-using patients with CRC could be drug-drug interactions between PPI and commonly used chemotherapeutics, such as capecitabine. However, neither study describes information on CRC treatment of their cohorts.

    Capecitabine is rapidly and predominantly absorbed from the upper GI tract[48 ]. It is thought that the dissolution and absorption of capecitabine may be reduced with increasing gastric pH (an effect produced by PPI)[49 ]. Sunet aland Wonget alstudied the drug interaction between PPI and capecitabine in patients diagnosed with CRC.After adjustment for confounders, these authors found conflicting evidence: Sunet al[40 ] reported similar RFS, but Wong et al[41 ] found significantly lower 3 -year RFS in the cohort concomitantly treated with CapeOx and PPI. These studies did not account for several potential confounders, such as concomitant drug use (statins, aspirin, antidiabetics), serious comorbidities, and treatment modifications, making it difficult to draw firm conclusions. Furthermore, a recent study by Sekidoet al[50 ] concluded that rabeprazole does not influence the plasma concentration of capecitabine and its metabolites, and subsequently their inhibitory effect on CRC cell proliferation.

    Several basic research studies have also focused on identifying potential anti-tumor mechanisms of PPIs in CRC. Three basic research studies revealed that PPI may exert anti-tumorigenic effects through several mechanisms: Reducing pro-inflammatory signaling molecules (TNF-α, COX-2 , and IL-6 ), oxidative stressors (NO and TBA-RS),and proteolytic enzymes (MMP-9 , MMP-11 , and MT1 -MMP); exerting anti-mitogenic effects (inhibition of MAPKs) and anti-angiogenic effects (hypoxia-inducible factor 1 -alpha, vascular endothelial growth factor, platelet-derived growth factor, IL-8 ); and inducing apoptosisviaupregulating pro-apoptotic molecules (p21 waf1 /cip1 ) and downregulating anti-apoptotic molecules (cyclin A, Bcl-2 , Bcl-xl and survivin)[23 ,24 ].Additionally, these studies also found that PPI could exert anti-tumor properties even when co-administered with gastrin. It seems that instead of enhancing the trophic effects of gastrin, PPI may paradoxically inhibit these effects by interfering with the interaction between gastrin and CCKBR[24 ].

    These results may explain the earlier findings of Penmanet al[20 ] and Tobi et al[21 ],who also used omeprazole in their work and found a protective effect of PPI on CRC.Zenget al[26 ] and Zheng et al[27 ] identified another potential action of specific PPI agents (pantoprazole, ilaprazole), as inhibitors of TOPK, a kinase highly expressed in rapidly proliferating tissues of embryological and cancerous origin[51 ]. The overexpression of TOPK in cancers has been associated with aggressive tumor behavior and poor clinical outcomes. Therefore, this kinase has been speculated to be a viable target for inhibiting downstream growth-promoting pathways[51 ]. Considering that no specific TOPK-inhibiting drugs have been approved for clinical use and the reported findings, further examination of these properties of pantoprazole and ilaprazole may be worthwhile.

    Figure 1 Figure outlining areas for future research to establish a better understanding of the relationship between proton pump inhibitors and colorectal cancer. CapeOx: Capecitabine plus oxaliplatin; CRC: Colorectal cancer; DFS: Disease free survival; FOLFOX: Fluorouracil, leucovorin, oxaliplatin; 5 -FU: 5 -flourouracil; MFS: Metastasis free survival; OME: Omeprazole; OS: Overall survival; PAN: Pantoprazole; PPI: Proton pump inhibitors; RCT: Randomized controlled trials; RFS: Recurrence free survival; TOPK: T lymphokine–activated killer cell-originated protein kinase.

    It has also been suggested that PPIs have chemosensitizing ability. This was highlighted by Wanget al[25 ] demonstrating that pantoprazole enhanced the cytostatic effect of FOLFOX in CRC. Chemoresistance has been associated with an acidic tumor microenvironment, which results from the increased production of lactic acid(Warburg effect) and/or overexpression of vacuolar-ATPase pumps[52 ,53 ]. It is thought that this microenvironment neutralizes the effects of chemotherapeutic agents while decreasing their uptake into cancer cells. PPI appear to inhibit the activity of vacuolar-ATPase pumps, thereby increasing the pH of cancer cells and sensitizing them to chemotherapeutics[54 ]. This mechanism may suggest a potential role for PPI as adjuvants during chemotherapy, not only for the symptomatic treatment of side effects but also to improve oncological outcomes. Zhanget al[39 ] further provided evidence to support this rationale by demonstrating lower recurrence rates and better chemoradiotherapy efficacy in patients using omeprazole concomitantly during chemotherapy compared with those did not.

    Various PPI agents have been developed on the basis of the prototype PPI,omeprazole. They all share structural similarities and are generally effective and safe in the treatment of acid-related disorders[6 ]. However, differences in pharmacokinetics and pharmacodynamics exist among them, with the newer agents offering several advantages[55 ]. Although these differences are primarily related to the onset of action and degree of acid suppression, they also include reduced potential for drug interaction and other potential mechanisms of action that could make them effective in the treatment of diseases other than acid-related disorders.

    Finally, it is important to mention that long-term PPI use also results in intestinal dysbiosis, with reduced abundance and diversity of gut microbiota and an increase in pathogenic bacteria[56 ]. Pathogenic bacteria implicated in the carcinogenesis of CRC,such asFusobacterium nucleatum,Escherichia coli,Enterococcus faecalis etc.are more prevalent in PPI users[57 ]. These bacteria form a special microenvironment in the colorectal tissue that is conducive to neoplastic transformation and progression. They produce toxins that can damage the intestinal cell barrier, dysregulate immune cell function, induce a chronic inflammatory state, and cause DNA damage and genomic instability, all of which increase cell proliferation and contribute to the development of CRC[57 ,58 ]. One group has found that the abundance ofFusobacterium nucleatummay be associated with chemoresistance in CRC, resulting in poor response to 5 -FU and oxaliplatin and higher recurrence rates[59 ]. This review did not identify any studies assessing the effect on CRC of intestinal dysbiosis resulting from PPI use. Studies focusing on the interaction of PPI-induced dysbiosis in CRC are needed to resolve the inconsistencies between the basic research and human studies.

    A major limitation of this review is the heterogeneity among the included studies.The basic research studies describe experiments with different animal models and cell lines, using different PPI doses and exposure periods, whereas the human (epidemiological and treatment) studies varied in accounting for potential confounding factors and inclusion criteria for PPI exposure. Additionally, most of the human studies used prescription databases to ascertain PPI use, which may fail to accurately determine PPI use because they do not account for prescription non-adherence and possible over-thecounter use. Moreover, stratification of epidemiological and treatment-related evidence based on the individual PPI agents was lacking in all but one included study.These limitations make it difficult to present conclusive evidence on the question of whether PPI are an adversary or an ally in relation to CRC. Nonetheless, this review is the first to systematize the entirety of current evidence on the topic, and summarize data from different levels and aspects of the relationship.

    In light of the evidence, we suggest that PPI use should continue when appropriately indicated, while a cautious approach should be implemented when combining them with capecitabine-based chemotherapy. Patients must be educated regarding the potential adverse effects of long-term PPI use and advised to avoid over-the-counter use for improper indications, with physicians being more diligent not to overprescribe.There are several aspects of this relationship which require further, high-quality investigation as outlined in Figure 1 .

    CONCLUSION

    In conclusion, this review highlights an unexpected potential beneficial role of specific PPI agents in relation to CRC. First, PPI instead of promoting CRC growthviatrophic effects of hypergastrinemia, may paradoxically inhibit them. Second, current evidence suggests that individual PPI agents may affect CRC differently: Pantoprazole and ilaprazole as TOPK inhibitors; rabeprazole with lower drug interaction capability with capecitabine; and pantoprazole and rabeprazole with little impact on CRC incidence(as evidenced by Leiet al[36 ])[26 ,27 ,50 ]. These findings warrant further studies to better understand these mechanisms and possibly facilitate use of PPI differently in clinical practice.

    ARTICLE HIGHLIGHTS

    国产亚洲午夜精品一区二区久久| 在线观看一区二区三区激情| 日本黄色日本黄色录像| 午夜福利在线观看吧| 亚洲精品乱久久久久久| 国产成人免费无遮挡视频| 国产日韩欧美视频二区| a级片在线免费高清观看视频| 交换朋友夫妻互换小说| 欧美少妇被猛烈插入视频| 夜夜骑夜夜射夜夜干| 婷婷色av中文字幕| 国产在线免费精品| 亚洲国产av新网站| 亚洲精品国产av成人精品| 91字幕亚洲| 久久久水蜜桃国产精品网| 青草久久国产| 黄色怎么调成土黄色| 亚洲成人免费电影在线观看| 亚洲久久久国产精品| 交换朋友夫妻互换小说| 搡老乐熟女国产| 欧美日韩精品网址| 另类亚洲欧美激情| 一区二区三区精品91| √禁漫天堂资源中文www| 免费日韩欧美在线观看| 巨乳人妻的诱惑在线观看| 国产有黄有色有爽视频| 亚洲av男天堂| 欧美精品啪啪一区二区三区 | 国产精品九九99| 国产色视频综合| 亚洲avbb在线观看| av免费在线观看网站| 波多野结衣av一区二区av| 久久女婷五月综合色啪小说| 久久久久视频综合| 老司机亚洲免费影院| av在线老鸭窝| 纵有疾风起免费观看全集完整版| 首页视频小说图片口味搜索| 欧美激情久久久久久爽电影 | 肉色欧美久久久久久久蜜桃| 中文字幕色久视频| 午夜激情av网站| 久久精品熟女亚洲av麻豆精品| 成年美女黄网站色视频大全免费| 亚洲国产中文字幕在线视频| 天堂俺去俺来也www色官网| 宅男免费午夜| 黄片大片在线免费观看| 一区二区三区四区激情视频| 色老头精品视频在线观看| 欧美国产精品va在线观看不卡| 美女大奶头黄色视频| 电影成人av| 伊人亚洲综合成人网| 亚洲av国产av综合av卡| 69精品国产乱码久久久| 国产欧美日韩综合在线一区二区| 各种免费的搞黄视频| 亚洲国产中文字幕在线视频| 国产99久久九九免费精品| 国产1区2区3区精品| 下体分泌物呈黄色| 亚洲精品中文字幕在线视频| 极品少妇高潮喷水抽搐| 少妇被粗大的猛进出69影院| 丝袜人妻中文字幕| 一级毛片女人18水好多| 精品亚洲乱码少妇综合久久| 亚洲av电影在线进入| 精品国产一区二区久久| 亚洲自偷自拍图片 自拍| 丁香六月天网| 大型av网站在线播放| 一级片'在线观看视频| 手机成人av网站| 午夜免费观看性视频| 亚洲国产欧美一区二区综合| 看免费av毛片| 久久久久久久国产电影| 亚洲一码二码三码区别大吗| 国产亚洲午夜精品一区二区久久| 一级毛片精品| 亚洲av成人一区二区三| 国产精品自产拍在线观看55亚洲 | 丰满迷人的少妇在线观看| 亚洲成人手机| 老司机影院成人| 免费一级毛片在线播放高清视频 | 免费看十八禁软件| 菩萨蛮人人尽说江南好唐韦庄| 一级毛片电影观看| 精品国内亚洲2022精品成人 | 欧美日韩福利视频一区二区| 在线观看免费高清a一片| 欧美日韩黄片免| 一二三四社区在线视频社区8| 午夜精品久久久久久毛片777| 久久99热这里只频精品6学生| 亚洲国产成人一精品久久久| 肉色欧美久久久久久久蜜桃| 两个人看的免费小视频| 三上悠亚av全集在线观看| 老司机影院毛片| 成人国语在线视频| 777久久人妻少妇嫩草av网站| 国产真人三级小视频在线观看| 亚洲av日韩在线播放| 亚洲国产中文字幕在线视频| 久久国产精品影院| 在线亚洲精品国产二区图片欧美| 午夜影院在线不卡| 久久精品亚洲av国产电影网| 国产1区2区3区精品| 在线观看人妻少妇| 这个男人来自地球电影免费观看| 真人做人爱边吃奶动态| 波多野结衣av一区二区av| 人成视频在线观看免费观看| 亚洲 欧美一区二区三区| 伊人久久大香线蕉亚洲五| 亚洲九九香蕉| 欧美大码av| 欧美亚洲日本最大视频资源| 男女之事视频高清在线观看| 制服人妻中文乱码| 国产日韩欧美亚洲二区| 免费看十八禁软件| 在线观看舔阴道视频| 国产精品久久久av美女十八| 久久精品亚洲av国产电影网| 亚洲专区字幕在线| 免费在线观看完整版高清| 欧美日韩一级在线毛片| 一本久久精品| 久久精品aⅴ一区二区三区四区| 日韩大码丰满熟妇| 久久国产亚洲av麻豆专区| 午夜福利视频在线观看免费| 久久久久国内视频| 精品卡一卡二卡四卡免费| 国产在线观看jvid| 后天国语完整版免费观看| 99久久综合免费| 国产xxxxx性猛交| 亚洲精品日韩在线中文字幕| 99久久综合免费| 国产精品香港三级国产av潘金莲| 久9热在线精品视频| 丰满少妇做爰视频| 男人添女人高潮全过程视频| 午夜精品久久久久久毛片777| 一本综合久久免费| 免费在线观看完整版高清| 一区二区av电影网| 老熟妇乱子伦视频在线观看 | 欧美一级毛片孕妇| 国产成人欧美| 国产成人精品无人区| 国产高清国产精品国产三级| 精品人妻一区二区三区麻豆| 久久久久久久久久久久大奶| netflix在线观看网站| 国产精品香港三级国产av潘金莲| 午夜老司机福利片| 精品少妇一区二区三区视频日本电影| 黄色视频,在线免费观看| 国产成人啪精品午夜网站| 超碰97精品在线观看| 老司机影院毛片| 欧美另类一区| 十八禁高潮呻吟视频| 亚洲黑人精品在线| 日本av手机在线免费观看| 欧美日韩亚洲高清精品| 中国美女看黄片| 天堂8中文在线网| 日韩 亚洲 欧美在线| 欧美国产精品一级二级三级| 69av精品久久久久久 | 男女午夜视频在线观看| 一本一本久久a久久精品综合妖精| 久久中文字幕一级| 亚洲伊人久久精品综合| 黄片播放在线免费| 99国产精品一区二区三区| 成人国产一区最新在线观看| 久久毛片免费看一区二区三区| 成年美女黄网站色视频大全免费| 国产国语露脸激情在线看| www.熟女人妻精品国产| a 毛片基地| 悠悠久久av| 人人妻人人澡人人爽人人夜夜| 亚洲综合色网址| 国产精品久久久久久精品古装| 亚洲av日韩精品久久久久久密| 亚洲综合色网址| 老司机靠b影院| 精品国产乱码久久久久久男人| 美女扒开内裤让男人捅视频| 国产成人a∨麻豆精品| 日韩制服骚丝袜av| 9色porny在线观看| 老熟妇仑乱视频hdxx| 19禁男女啪啪无遮挡网站| 亚洲熟女精品中文字幕| 黄频高清免费视频| 成人国产av品久久久| 女人久久www免费人成看片| 欧美日韩福利视频一区二区| 国产成人a∨麻豆精品| 中文字幕制服av| 国产成人精品在线电影| 亚洲国产欧美在线一区| a级毛片黄视频| 国产不卡av网站在线观看| 欧美成狂野欧美在线观看| 国产精品一区二区在线不卡| 亚洲三区欧美一区| 99国产精品免费福利视频| 国产欧美日韩精品亚洲av| 国产精品 国内视频| 午夜成年电影在线免费观看| a 毛片基地| 一本一本久久a久久精品综合妖精| 国产精品成人在线| 中文精品一卡2卡3卡4更新| 欧美激情久久久久久爽电影 | 欧美少妇被猛烈插入视频| 中文字幕高清在线视频| 国产精品久久久av美女十八| 国产麻豆69| 国产精品国产三级国产专区5o| 叶爱在线成人免费视频播放| 久久人人爽av亚洲精品天堂| 在线观看免费视频网站a站| 国产精品秋霞免费鲁丝片| 又紧又爽又黄一区二区| 欧美在线一区亚洲| 又黄又粗又硬又大视频| 久久精品人人爽人人爽视色| 亚洲欧洲精品一区二区精品久久久| 在线观看免费高清a一片| www.自偷自拍.com| 日本av免费视频播放| a级毛片黄视频| 国产成人精品在线电影| 一级毛片精品| 18禁国产床啪视频网站| 国产激情久久老熟女| 亚洲伊人色综图| 嫁个100分男人电影在线观看| 无限看片的www在线观看| 国产精品二区激情视频| 国产高清videossex| 午夜免费成人在线视频| 最黄视频免费看| 丝袜脚勾引网站| 久久精品人人爽人人爽视色| 精品国内亚洲2022精品成人 | 亚洲欧美精品综合一区二区三区| 久久精品国产亚洲av高清一级| 99国产精品99久久久久| 宅男免费午夜| svipshipincom国产片| 97在线人人人人妻| 在线观看免费午夜福利视频| 亚洲精品国产区一区二| 欧美日韩成人在线一区二区| 777久久人妻少妇嫩草av网站| 人人妻人人澡人人爽人人夜夜| 91老司机精品| 久久亚洲国产成人精品v| 老司机午夜福利在线观看视频 | 一区福利在线观看| 亚洲精品乱久久久久久| 无遮挡黄片免费观看| 日本av免费视频播放| 精品福利观看| 大型av网站在线播放| 久久精品国产综合久久久| 捣出白浆h1v1| 国产高清videossex| 欧美在线黄色| 狂野欧美激情性xxxx| 国产欧美日韩一区二区三区在线| 亚洲熟女精品中文字幕| 亚洲精品中文字幕在线视频| 成人手机av| 一二三四在线观看免费中文在| 精品国产一区二区三区久久久樱花| 亚洲色图综合在线观看| 日本黄色日本黄色录像| 精品少妇久久久久久888优播| 少妇被粗大的猛进出69影院| 欧美少妇被猛烈插入视频| 在线观看一区二区三区激情| 久久久久视频综合| 国产一区有黄有色的免费视频| 亚洲国产av新网站| www.自偷自拍.com| 国产麻豆69| 12—13女人毛片做爰片一| 亚洲av国产av综合av卡| 侵犯人妻中文字幕一二三四区| 最近最新中文字幕大全免费视频| 欧美人与性动交α欧美软件| 黄频高清免费视频| 欧美 亚洲 国产 日韩一| 人人妻人人澡人人爽人人夜夜| 黄色怎么调成土黄色| 国产91精品成人一区二区三区 | 久久国产精品影院| 亚洲一区二区三区欧美精品| 久久久久国产精品人妻一区二区| 亚洲av欧美aⅴ国产| 亚洲va日本ⅴa欧美va伊人久久 | 亚洲天堂av无毛| 性少妇av在线| 亚洲一码二码三码区别大吗| 国产成人免费观看mmmm| 日韩免费高清中文字幕av| 久久精品熟女亚洲av麻豆精品| 十八禁人妻一区二区| 青青草视频在线视频观看| 人人妻,人人澡人人爽秒播| 国产亚洲精品久久久久5区| 少妇的丰满在线观看| 久久国产精品影院| 蜜桃在线观看..| 午夜老司机福利片| 在线十欧美十亚洲十日本专区| 他把我摸到了高潮在线观看 | 日韩大码丰满熟妇| 色视频在线一区二区三区| 80岁老熟妇乱子伦牲交| 亚洲精品国产色婷婷电影| 午夜免费观看性视频| 色综合欧美亚洲国产小说| av在线老鸭窝| 自拍欧美九色日韩亚洲蝌蚪91| 波多野结衣av一区二区av| 夜夜夜夜夜久久久久| 国产在线一区二区三区精| 欧美日韩福利视频一区二区| 嫩草影视91久久| av福利片在线| 乱人伦中国视频| 99热国产这里只有精品6| 久久久久久久大尺度免费视频| 日本av免费视频播放| 另类精品久久| 国产一区二区三区av在线| 另类精品久久| 别揉我奶头~嗯~啊~动态视频 | 国产精品亚洲av一区麻豆| 国产在线一区二区三区精| 久久久精品国产亚洲av高清涩受| 韩国精品一区二区三区| 国产色视频综合| 亚洲欧美清纯卡通| 纯流量卡能插随身wifi吗| 秋霞在线观看毛片| 一二三四社区在线视频社区8| 久久久国产成人免费| 色播在线永久视频| 18禁国产床啪视频网站| 日本一区二区免费在线视频| 亚洲自偷自拍图片 自拍| 国产精品久久久人人做人人爽| 69av精品久久久久久 | 伦理电影免费视频| 亚洲国产成人一精品久久久| 亚洲黑人精品在线| 国产av国产精品国产| 韩国精品一区二区三区| 老鸭窝网址在线观看| av国产精品久久久久影院| 欧美黑人精品巨大| 国产欧美日韩综合在线一区二区| 侵犯人妻中文字幕一二三四区| 成在线人永久免费视频| 久久久久久久精品精品| 日韩三级视频一区二区三区| 99久久综合免费| 国产精品自产拍在线观看55亚洲 | 久久久久久久久免费视频了| 国产欧美日韩精品亚洲av| av国产精品久久久久影院| kizo精华| 成人18禁高潮啪啪吃奶动态图| 国产真人三级小视频在线观看| 亚洲色图 男人天堂 中文字幕| 亚洲精品国产区一区二| 视频区图区小说| 日本五十路高清| 欧美黄色淫秽网站| 午夜免费观看性视频| 久久久精品94久久精品| 十八禁网站免费在线| 一级毛片精品| 香蕉丝袜av| 久久久久网色| 汤姆久久久久久久影院中文字幕| 飞空精品影院首页| 日本五十路高清| 少妇人妻久久综合中文| 欧美精品高潮呻吟av久久| 久久久国产一区二区| 少妇被粗大的猛进出69影院| 人人妻人人添人人爽欧美一区卜| 成人免费观看视频高清| 中文字幕精品免费在线观看视频| 纵有疾风起免费观看全集完整版| 久久人人爽人人片av| 香蕉国产在线看| 国产一级毛片在线| 日本wwww免费看| 涩涩av久久男人的天堂| 午夜久久久在线观看| 午夜福利一区二区在线看| 欧美久久黑人一区二区| 性高湖久久久久久久久免费观看| av电影中文网址| 永久免费av网站大全| 少妇 在线观看| tocl精华| 97在线人人人人妻| 亚洲国产中文字幕在线视频| 黄片小视频在线播放| 亚洲精品av麻豆狂野| 色94色欧美一区二区| 亚洲精品国产av成人精品| 欧美精品一区二区大全| 久久国产精品影院| 欧美日韩一级在线毛片| 久久久国产欧美日韩av| svipshipincom国产片| 99精品欧美一区二区三区四区| 精品少妇久久久久久888优播| 午夜福利免费观看在线| 老司机深夜福利视频在线观看 | 亚洲国产欧美日韩在线播放| 三级毛片av免费| 天天躁狠狠躁夜夜躁狠狠躁| 国产高清videossex| 日本黄色日本黄色录像| 国产亚洲精品一区二区www | 精品一品国产午夜福利视频| 超色免费av| 一级a爱视频在线免费观看| 女性生殖器流出的白浆| 亚洲第一欧美日韩一区二区三区 | 色播在线永久视频| 纯流量卡能插随身wifi吗| 成年人黄色毛片网站| 秋霞在线观看毛片| 久久久久久久久久久久大奶| 国产精品久久久久成人av| 视频区欧美日本亚洲| av国产精品久久久久影院| 久久av网站| 亚洲av电影在线观看一区二区三区| 久久精品国产亚洲av香蕉五月 | 国产免费福利视频在线观看| 国产日韩欧美视频二区| 热99re8久久精品国产| 国产亚洲av片在线观看秒播厂| 多毛熟女@视频| 十八禁网站免费在线| 9191精品国产免费久久| 精品福利永久在线观看| 国产无遮挡羞羞视频在线观看| 精品国产一区二区久久| 天天躁夜夜躁狠狠躁躁| 久久久国产成人免费| 伦理电影免费视频| 亚洲中文字幕日韩| 天堂中文最新版在线下载| 中文字幕av电影在线播放| 亚洲第一青青草原| 国产成人啪精品午夜网站| 巨乳人妻的诱惑在线观看| 十分钟在线观看高清视频www| 伊人久久大香线蕉亚洲五| 99精品久久久久人妻精品| 亚洲中文字幕日韩| 欧美亚洲 丝袜 人妻 在线| 一级a爱视频在线免费观看| 一级片免费观看大全| 国产老妇伦熟女老妇高清| 欧美激情高清一区二区三区| 91九色精品人成在线观看| 久久国产精品大桥未久av| 王馨瑶露胸无遮挡在线观看| 性高湖久久久久久久久免费观看| 免费一级毛片在线播放高清视频 | 一个人免费在线观看的高清视频 | 俄罗斯特黄特色一大片| 97精品久久久久久久久久精品| 精品熟女少妇八av免费久了| 久久精品熟女亚洲av麻豆精品| 久久99热这里只频精品6学生| 欧美激情高清一区二区三区| 建设人人有责人人尽责人人享有的| 欧美日韩福利视频一区二区| 精品视频人人做人人爽| 日日爽夜夜爽网站| 大型av网站在线播放| 飞空精品影院首页| 色综合欧美亚洲国产小说| 91精品三级在线观看| 无限看片的www在线观看| 国产精品偷伦视频观看了| 国产日韩欧美亚洲二区| 欧美大码av| 99精国产麻豆久久婷婷| 国产日韩欧美视频二区| 国产97色在线日韩免费| 一本一本久久a久久精品综合妖精| 在线观看舔阴道视频| a在线观看视频网站| 精品亚洲乱码少妇综合久久| 国产片内射在线| 性高湖久久久久久久久免费观看| 欧美日韩精品网址| 99香蕉大伊视频| 涩涩av久久男人的天堂| 黑人欧美特级aaaaaa片| 捣出白浆h1v1| 日日夜夜操网爽| 国产欧美日韩一区二区三 | 免费高清在线观看视频在线观看| 丝袜脚勾引网站| 亚洲精品中文字幕一二三四区 | 色婷婷久久久亚洲欧美| 免费观看av网站的网址| 久久精品亚洲熟妇少妇任你| 国内毛片毛片毛片毛片毛片| 欧美人与性动交α欧美软件| 久久99一区二区三区| 97人妻天天添夜夜摸| 亚洲激情五月婷婷啪啪| 亚洲三区欧美一区| 亚洲熟女精品中文字幕| 男人舔女人的私密视频| 黄色片一级片一级黄色片| 国产深夜福利视频在线观看| 亚洲色图 男人天堂 中文字幕| 999久久久精品免费观看国产| 久久九九热精品免费| 丝袜在线中文字幕| 久久这里只有精品19| 韩国精品一区二区三区| 18禁裸乳无遮挡动漫免费视频| 搡老岳熟女国产| 久久久久精品国产欧美久久久 | 黄色毛片三级朝国网站| 色精品久久人妻99蜜桃| 91成人精品电影| 精品少妇久久久久久888优播| 99国产精品一区二区蜜桃av | 亚洲精品在线美女| 爱豆传媒免费全集在线观看| 日韩三级视频一区二区三区| 亚洲精品一卡2卡三卡4卡5卡 | 悠悠久久av| 国产亚洲午夜精品一区二区久久| 免费高清在线观看日韩| 免费在线观看视频国产中文字幕亚洲 | 少妇被粗大的猛进出69影院| 视频区欧美日本亚洲| 99精品久久久久人妻精品| 精品卡一卡二卡四卡免费| 久久精品亚洲熟妇少妇任你| 青春草视频在线免费观看| 美女主播在线视频| 曰老女人黄片| 色94色欧美一区二区| 欧美一级毛片孕妇| 亚洲全国av大片| a在线观看视频网站| 超碰成人久久| 女性生殖器流出的白浆| 欧美少妇被猛烈插入视频| 亚洲伊人色综图| 别揉我奶头~嗯~啊~动态视频 | 久久中文字幕一级| 91老司机精品| 国产伦人伦偷精品视频| 国产无遮挡羞羞视频在线观看| 老司机午夜福利在线观看视频 | 大香蕉久久网| 亚洲精品一卡2卡三卡4卡5卡 | 国产一级毛片在线| 91麻豆av在线| 岛国毛片在线播放| 国产精品久久久久久精品电影小说| 亚洲欧美成人综合另类久久久| 欧美av亚洲av综合av国产av| 日本av手机在线免费观看| 国产成人精品久久二区二区91| 少妇粗大呻吟视频| 亚洲avbb在线观看| 久久精品人人爽人人爽视色| 午夜两性在线视频| 精品欧美一区二区三区在线| 99re6热这里在线精品视频| 欧美激情久久久久久爽电影 | 欧美日韩国产mv在线观看视频|